Danaher Stock News

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management.

Quality shareholders gravitate to quality companies, with frequently lucrative results.

DUBLIN , Feb. 18, 2022 /PRNewswire/ -- The "Global Laboratory Consumables Market 2021" report has been added to ResearchAndMarkets.com''s offering. The Global Laboratory Consumables Market report is designed for general management, product managers and marketing executives in the laboratory consumables industry. For them, it provides up-to-date market data about those technologies in their areas of interest. and related markets. Information on specific segments or the whole industry can be used to evaluate markets, the competitive landscape, or identify opportunities and acquisition targets. A strategy for the consumables market must involve geographic market composition, market growth rate, and new competitors. This report saves time by providing comprehensive data in an easily readable format. Companies covered in the report include: Agilent Beckman Coulter Bio-Rad Danaher Eppendorf GE Healthcare Hitachi High Technologies Illumina Lonza … Full story available on Benzinga.com

Sector ETF report for PTH

Danaher (NYSE: DHR ) has outperformed the market over the past 10 years by 8.65% on an annualized basis. Buying $1,000 In DHR: 10 years ago, an investor could have purchased 24.79 shares of Danaher at the time with $1,000. This investment in DHR would have produced an average … Full story available on Benzinga.com

General Electric (GE) decides to reshape its steam power portfolio by divesting certain businesses to the EDF Group. It expects to record non-cash charges related to the deal.

WASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Pharmaceutical Membrane Filtration Market finds that growth in the production of biopharmaceuticals is expediting market growth. Primarily driven by advancements in nanofiltration technologies, the total global Pharmaceutical Membrane Filtration Market is estimated to reach USD 14.16 Billion by 2028, up from USD 6.48 Billion in 2021, at a Compound Annual Growth Rate (CAGR) of 11.8%. Furthermore, the surging adoption of single-use technologies is also anticipated to augment the growth of the global Pharmaceutical Membrane Filtration Market, states Vantage Market Research, in a report, titled: " Pharmaceutical Membrane Filtration Market by Product (Filters, Systems, Accessories), by Technique (Microfiltration, Ultrafiltration, Nanofiltration, Reverse Osmosis), by Material (PES, PVDF, Nylon, PTFE), by Application (Final Product Processing, API Filtration, Sterile Filtration, Protein Purification), by Region (North America, Europe, Asia Pacific, Middle East & Africa) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Related Stocks: DHR , FTNT , WST , PANW , ABNB , ANET , LCID , ZS , QFIN , TX , BRKR , VAL , CLDR , XLRN , BBL , CHKP , VER , FOX ,

Danaher''s recent underperformance is a reason to buy shares, according to UBS, who has added the stock to its list of Pricing Power Standouts.

Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Global Fecal Occult Testing Market 2021-2025" report has been added to ResearchAndMarkets.com''s offering. The global fecal occult testing market is poised to grow by $113.49 million during 2021-2025, progressing at a CAGR of 4.41% during the forecast period. The market is driven by rising geriatric population and increasing prevalence of CRC. The study identifies the increasing number of government initiatives for CRC screening tests as one of the prime reasons driving the fecal occult testing market growth during the next few Full story available on Benzinga.com

The life sciences and diagnostics company will do well if the pandemic gets worse.

The life sciences and diagnostics company will do well if the pandemic gets worse.

Nasdaq futures traded sharply lower this morning after Meta Platforms, Inc. (NASDAQ: FB) reported worse-than-expected Q4 EPS results and issued weak forecast. When insiders sell shares, it indicates t